ovarian cancer 7 l a v i 60% - astrazeneca · for ge ntic s 3 brca1 and brca2 belong to a type of...
TRANSCRIPT
with aBRCA2 mutation
11-17%of women
Up to
References:1 Cancer Research UK: Risk Factors for Ovarian Cancer. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/riskfactors/ Last accessed: March 20172 SEER Cancer Factsheets: Ovary cancer. SEER 18 2003-2009. Available at: http://seer.cancer.gov/statfacts/html/ovary.html Last accessed: March 20173 Gadzicki D, et al. Genetic testing for familial/hereditary breast cancer—comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet. 2011;2:53-69.4 National Cancer Institute. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA Last accessed: March 20175 Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.6 World Cancer Research Fund. Ovarian cancer statistics. Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovarian-cancer-statistics Last accessed; March 2017
© 2
017
Astra
Zene
ca. A
ll Rig
hts
Rese
rved
Ovarian cancer is the 7th most commonly diagnosed cancer in women worldwide 6
Several factors may influence the development and prognosis of ovarian cancer, including 1,2:
of ovarian cancers are diagnosed at the advanced stage 2
Familyhistory
92%
73%
28%
Stage I
StageII/III
StageIV
5-YE
AR S
URV
IVAL
5-year survival
decreases significantly
with stage of diagnosis2
Lifestylefactors
Environmental factors
Age Earlydiagnosis
OVARIAN CANCER AND GENETIC TESTINGGenetic mutations can play a role in the development and treatment of cancerIndividuals at risk of carrying a genetic mutation can be referred for genetic testing3
BRCA1 and BRCA2 belong to a type of genes
known as tumour suppressors 4
The risk of developing ovarian cancer is increased in women with specific inherited genetic abnormalities. One of these risks is associated with BRCA mutations5
will develop ovarian cancer
by age 70 years
4
in the generalpopulation
About 1.3% of women
with aBRCA1 m ationut
Up to 39% of women
60% Up to
of women who inherit a BRCA1
mutation are likely to develop ovarian
cancer
4
Up to
of women who inherit a BRCA2
mutation are likely to develop ovarian
cancer
39%
11 - 17%
Docu
men
t Num
ber:
Z4-4
913
D
ate
of P
rep:
May
201
7
Dat
e of
exp
iry: M
ay 2
018